Позитивные эффекты небиволола у пациентов с хроническими обструктивными заболеваниями лёгких
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.45Ключевые слова:
хроническая обструктивная болезнь лёгких, эндотелиальная функция, сосудистая дисфункцияАннотация
Помимо кардиоселективности и вазодилатирующих эффектов, обусловленных высвобождением оксида азота, было продемонстрировано что небиволол обладает противовоспалительным эффектом, существенно улучшает эндотелиальную функцию и уменьшает артериальную регидность, что позволяет полагать, что лечение небивололом у пациентов с легочной патологией, помимо снижения уровня артериального давления, обладает рядом преимуществ. До настоящего времени клинические исследования с небивололом были проведены в короткий период и у ограниченного количества пациентов. Польза от использования небиволола не зависела от наличия конкретной сердечно-сосудистой патологии, от использования в лечении других кардиологических препаратов и не была связана с побочными эффектами в отношении легочной функции. Интересен тот факт,что было продемонстрировано существенное снижение смертности от любых причин у пациентов с ХОБЛ и артериальной гипертензией, получавших кардиоселективные бета-адреноблокаторы.
Библиографические ссылки
Mannino D.M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(suppl 5): 121S-126S.
Buist A. S., McBurnie M.A. , Vollmer W.M., et al. International variation in the prevalence of COPD (the BOLD Study): a population- based prevalence study. Lancet. 2007;370:741-750.
Halbert R. J. , Natoli J. L. , Gano A. , et al. Global burden pf COPD: systematic review and meta- analysis. Eur Respir J. 2006:28:523-532.
Lopez A.D., Mathers C.D., Ezzati M., et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-1757.
Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204-212.
Hole D.J., Watt G.C., Davey-Smith G., et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711-715; discussion 715-716.
Hospers J.J., Postma J.D.S., Rijcken B. et al. Histamine airway hyperresponsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000:356:1313-1317.
Schunemann H.J. Dorn J., Grant B.J., et al. Pulmonary function is a long-term predictor of mortality in. the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;l18:656-664.
Speizer F.E. Fay M.E., Dockery D.W., Ferris B.G. Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis. 1989;2:S49-S55.
Tockman M.S., Pearson J.D., Fleg J.L., Fleg J.L. Rapid decline in FEV1. A new risk factor for coronarv heart disease mortality. Am J Respir , Crit Care Med. 1995;1:390-398.
Finkelstein J., Cha E., Scharf S.M. Chronic obstructiye pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337-349.
Ashrafian H., Violaris A.G. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma dr COPD: the pro viewpoint. Prim Care Respir J. 2005;14:236-241.
Salpeter S, OrmisronT, Salpeter E. Cardioselectivebeta- blockers for chronic obstructive pulmonary disease. Cochrane Database SystRev. 2005;(4):CD003566.
Mason RP, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens. 2006;8(suppl 12):40- 52.
Lee TA, Pickard AS, Au DH, et al. Risk for death associated withmedications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008; 149:380-390.
Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010;8:638-644.
Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res. 2003;26:609-614.
Mancini GB, Ettninan M, Zhang B, er al. Reduction of morbidity and mortality by statins, angiotensin- converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554-2560.
Milnzel T, Gori T. Nebivolol: the somewhat-different β-adrenergic receptor blocker. J Am Coll. Cardiol. 2009;54:1491-1499.
Wolf SC, Sauter G, Preyer M, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after, balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem. 2007;4:129-136.
Mason RP, Kalinowski L, Jacob RE, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 20.05; 112:3795-3801.
Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, doubleblind. crossover study. Circulation. 2001;104:511-514.
McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increasesarterial distensibility in vivo. Hypertension. 2004;44:305-310.
Dal Negro R. Pulmonary effects of nebivolol. Ther Adv CardiovascDis. 2009;3:329-334.
Cazzola M, Matera MG, Ruggeri P, et al. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration. 2004;71:159-164.
lakushin SS, Okorokov VG, Liferov RA, et al. Assessment ofsafety and antihypertensive efficacy of a cardioselective beta-blocker nebivolol in patients with hypertension and concomitant chronicobstructive bronchitis. Kardiologiia. 2002;42:36-39.
Murthys H, Giebelhaus V, Von Fallois J. Nebivolol (nebilet) a β-blocker of the third generation - also for patients with obstructive lung diseases?. Z Kardiol. 2001;90:760-765.
Kotlyar E, Keogh AM, Macdonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21:1290-1295.
Jabbour A, Macdonald PS, Keogh AM, et al. Differences between β-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-1787.
Au DH, Bryson CL, Fan VS, et al. B-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med. 2004; 117:925-931.
Rutten FH, Zuithoff NP, Hak E, et al. B-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.
Short PM, Lipworrh SI, Elder DH, et al. Effect of beta-blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study, BMJ. 201 l;342:d2549.
Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment, of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53-67.
Rennard SI, Fogarty C, Keisen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonarydisease. Am J Respir Crit Care Med. 2007;175:926-934.
Sin D.D., Man S.F. Chronic obstructive pulmonary disease as a risc factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005; 2:8-11.
Martîniuc C., Braniște T. The use of beta-blocker Nebivilol in patients with chronic pulmonary disease in association with arterial hypertension. Revistă medico-chirurgicală. Iasi, Romania. 2012, 116(1), 218-221.
Загрузки
Опубликован
Лицензия
Copyright (c) 2025 Вестник Академии Наук Молдовы. Медицина
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
